This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and ClearPoint Neuro, Inc. (CLPT) have performed compared to their sector so far this year.
Acadia Healthcare (ACHC) JV to Build Behavioral Health Hospital
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with Massachusetts-based Tufts Medicine to construct a behavioral health hospital and address the dire need for better behavioral healthcare services across Boston.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Acadia Healthcare (ACHC) Down 4.5% Since Last Earnings Report?
by Zacks Equity Research
Acadia Healthcare (ACHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Acadia Healthcare (ACHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Acadia Healthcare (ACHC) Dips 1.6% Despite Q1 Earnings Beat
by Zacks Equity Research
Acadia Healthcare (ACHC) aims to add around 300 beds to its existing facilities in 2022.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Has Acadia Healthcare (ACHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.
Mednax (MD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 22.22% and 1.75%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Community Health Systems (CYH) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 7.69% and 1.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Acadia Healthcare (ACHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health (UHS) Q1 Earnings Miss Mark, Tumble Y/Y
by Zacks Equity Research
Universal Health's (UHS) Q1 results reflect a steep expense level and lower admissions in its Behavioral Health Care Services segment, partially offset by revenue recognition.
Tenet Healthcare (THC) Q1 Earnings Beat Mark, Surge Y/Y
by Zacks Equity Research
Tenet Healthcare (THC) Q1 earnings gain from a healthy revenue stream, reduced expenses and operational efficiency.
Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.
What to Expect Ahead of HCA Healthcare's (HCA) Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q1 earnings are likely to reflect gain from better admissions and a higher revenue stream.
UnitedHealth's (UNH) Q1 Earnings Surpass Mark, Improve Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) Q1 results reflect gains from both its segments, Optum and UnitedHealthcare, along with higher revenues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Acadia Healthcare (ACHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Acadia Healthcare (ACHC) Up 12.2% Since Last Earnings Report?
by Zacks Equity Research
Acadia Healthcare (ACHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia Healthcare (ACHC) Up 10% in 3 Months: More Room to Run?
by Zacks Equity Research
Solid demand for behavioral healthcare services, multiple growth-related initiatives and a solid cash balance are driving Acadia Healthcare (ACHC).
Acadia Healthcare (ACHC) JV Adds Service Line, Ups Bed Capacity
by Zacks Equity Research
Acadia Healthcare (ACHC) operated (through a JV) Southcoast Behavioral Health includes a pediatric service line and increases bed capacity to 192.
Acadia Healthcare (ACHC) Eyes Over 600 Bed Additions in 2022
by Zacks Equity Research
Acadia Healthcare (ACHC) has two de novo projects in Chicago and Indio, CA, which are expected to add a total of around 140 beds this year.
Why Acadia Healthcare (ACHC) Stock Might be a Great Pick
by Zacks Equity Research
Acadia Healthcare (ACHC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Acadia Healthcare (ACHC) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's How Mednax (MD) Can Gain By Adopting the Pediatrix Brand
by Zacks Equity Research
Mednax (MD) bringing some of its operations under the Pediatrix brand is expected to collectively promote its wide range of healthcare services.